Abbott Laboratories

Strong Q1 Performance: Abbott Laboratories achieved high single-digit sales growth (7%) with double-digit earnings per share (EPS) growth (11% YOY), reaching an adjusted EPS of $1.09, in line with guidance. Excluding COVID-19 testing sales, growth was over 8%, supporting the company's robust operational execution.

Positive Guidance Extending to FY 2025: Abbott maintained its full-year financial guidance despite the potential financial impact from new tariff policies. The company is estimated to face a few hundred million dollars in tariff impacts in 2025, primarily affecting U.S. and China operations but remains optimistic about a resilient growth trajectory.

Diagnostic Business Challenges: The diagnostics segment reported a 5% decline in sales due to lower COVID-19 testing sales, emphasizing the specific adverse effects from volume-based procurement in China. The reliance on pricing pressure in that market limits short-term growth, although the company is focusing on long-term recovery strategies here.